12:00 AM
 | 
Jul 30, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Prezista darunavir regulatory update

EMA's CHMP issued a positive opinion to expand the indication of Prezista darunavir from Johnson & Johnson to include treatment of HIV-1 infection in antiretroviral therapy-experienced pediatric...

Read the full 113 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >